P
RCKT icon

Pitcairn’s Rocket Pharmaceuticals RCKT Stock Holding History

Pitcairn’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,089
Closed -$217K – 750
2024
Q2 		$217K Buy
10,089
+725
+8% +$16.7K 0.01% 676
2024
Q1 		$252K Buy
9,364
+254
+3% +$7.21K 0.02% 632
2023
Q4 		$273K Buy
+9,110
New +$201K 0.02% 566

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Pitcairn's RCKT Position: Q3 2024 in Review

Pitcairn sold out of Rocket Pharmaceuticals (RCKT) in Q3 2024, closing a stake of 10,089 shares — an estimated $217K sold.

Pitcairn first reported a position in RCKT in Q4 2023 and held it in 3 quarters. The position peaked at $273K in Q4 2023. 191 funds tracked by Wall St. Rank hold RCKT as of Q3 2024.

  • Pitcairn reported no remaining Rocket Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pitcairn sold 10,089 Rocket Pharmaceuticals shares in Q3 2024, an estimated $217K.
  • Pitcairn first reported a position in Rocket Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Pitcairn's Rocket Pharmaceuticals position peaked at $273K in Q4 2023.
  • 191 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2024.

Based on Pitcairn's 13F filing for Q3 2024, filed 12 Nov 2024.